Clinical Trial Update: Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating dinutuximab plus irinotecan versus irinotecan alone in relapsed or refractory small cell lung cancer has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• dinutuximab (dinutuximab)

Snippet

Sponsor: United Therapeutics | Conditions: Small Cell Lung Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-12-09